There is a growing demand for generic drugs in Malaysia. The government is the largest pharmaceutical buyer in Malaysia and is responsible for more than half of the purchasing value. The Indian, Chinese, and other similar drug manufacturers have begun playing a dominant role in the Malaysian pharmaceutical market. In Malaysia, the pharmaceutical manufacturing sector […]

Read More →

The Philippines is the third-largest pharmaceutical market in ASEAN after Thailand and Indonesia. In 2019, total generic drug sales were in the Philippines were PHP82.3 billion, and accounts for 63% of prescription sales and estimate to reach PHP110 Billion by 2024. The highest cost of medicines in the Philippines among other ASEAN countries is one […]

Read More →

Orphan drug designation for rare disease qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing, so let’s know more about Orphan drug designation Worldwide orphan drug sales are forecast to grow at a CAGR of 12.3% from 2019 to 2024, which is approximately double […]

Read More →